



Learn about QuantiFERON[®]-TB Gold Plus from the experts

The US CDC now recommends TB blood tests, like QuantiFERON-TB Gold Plus, for the majority of the US testing population (1). Doctors and hospitals trust QFT[®]-Plus to provide accurate, cost-effective testing in a single patient visit. To learn more about the benefits of QFT-Plus testing and hear about the latest testing guidelines from the CDC, USCIS, AAP and more, visit one of our free online webinars using the links below!

What's the 'Plus' in QuantiFERON-TB Gold Plus?



QFT-Plus features innovative CD8 T cell technology that provides clinicians with a more comprehensive picture of a patient's immune response to TB. Recent publications illustrate the benefits of QFT-Plus technology for at-risk patient populations – including in contact investigation, healthcare worker screening and immunocompromised patients.

Join **Dr. Masae Kawamura** for a discussion of the latest scientific advancements in TB testing and CD8 technology, including a review of recent publications and a discussion of case scenarios applying the insights of QFT-Plus. Dr. Masae Kawamura is a former TB Controller and current Senior Director of Scientific and Medical Affairs for TB diagnostics, QIAGEN.

 View this webinar at go.qiagen.com/PlusRecording

Risk-based TB screening: A primary care approach to TB elimination



Primary care providers – particularly those working in public and community health centers – can lead the US effort to eliminate tuberculosis by implementing comprehensive, risk-based TB screening programs.

Join **Dr. Scott Lindquist**, MD, MPH, to learn about the most recent recommendations on TB testing and how IGRA-based screening programs can support TB elimination efforts while increasing efficiencies at the practice level. Dr. Lindquist has focused his career on underserved populations and infectious diseases, and currently serves as the State Epidemiologist for Communicable Diseases and Deputy Health Officer for Washington State.

 View this webinar at go.qiagen.com/TBelimination

Implementing IGRA: The benefits of TB blood testing for university student health programs

A proactive approach to TB prevention is critical to the health of university students and faculty. Updated guidelines from the American College Health Association (ACHA) now state that all incoming students should be screened for TB risk factors via questionnaire, and those with an identifiable risk factor should be tested for latent TB infection. Colleges and universities across the country are discovering the accuracy and efficiency benefits of choosing TB blood testing (IGRAs) to meet their testing needs for students and staff.

Join **Dr. Masae Kawamura** to learn about the most recent US TB testing recommendations and how IGRA-based testing can improve the effectiveness of college screening programs while increasing the efficiency of health center operations.



 View this webinar at go.qiagen.com/StudentHealthRecording

Rethinking TB testing and treatment in Pediatrics: insights from the 2018 AAP recommendations

On June 1, the American Academy of Pediatrics released the new Red Book® 2018 edition. The AAP now preferentially recommends the use of TB blood tests (IGRAs) in BCG-vaccinated children aged 2 years and older. Moreover, for all children 2 years or older, an IGRA may be used in any situation where a TST would historically be used.

Join **Dr. Sonia Qasba** to learn the rationale behind the 2018 AAP recommendations. You'll also learn why TB elimination efforts are increasingly focused on employing preventive methods in the primary care setting. Dr. Qasba a physician at Suburban Hospital, part of Johns Hopkins Medicine, and is board certified in Infectious Disease, Internal Medicine, and Pediatrics.



 View this webinar at go.qiagen.com/PediatricsRecording

Understanding the new USCIS TB testing guidelines for immigrations exams



Beginning October 1, 2018, the tuberculin skin test (TST) is no longer being accepted for USCIS immigration exams. Instead, a TB blood test (interferon-gamma release assay or IGRA) is required for permanent resident applicants ages 2 and older. While an individual with a positive IGRA will be able to complete the status adjustment process, LTBI positive results must be reported to the local health department.

Join **Dr. Alawode Oladele** as he introduces the new IGRA requirement and the updated technical instructions. Learn how to interpret and manage IGRA results, and why this change is an important step in the CDC's march toward TB elimination in the US. Dr. Oladele is the medical director of countywide services for the DeKalb County Board of Health, Georgia.

 View this webinar at go.qiagen.com/USCISrecording

Ready to learn more? Talk to your local QuantiFERON sales representative, or visit **www.QuantiFERON.com**!

QFT-Plus is an in vitro diagnostic aid for detection of *Mycobacterium tuberculosis* infection. QFT-Plus is an indirect test for *M. tuberculosis* infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. The USA format of the QFT-Plus test has not been extensively evaluated with specimens from individuals who have impaired or altered immune functions, such as those who have HIV infection or AIDS, those who have transplantation managed with immunosuppressive treatment or others who receive immunosuppressive drugs (e.g., corticosteroids, methotrexate, azathioprine, cancer chemotherapy), those who have other clinical conditions, such as diabetes, silicosis, chronic renal failure, and hematological disorders (e.g., leukemia and lymphomas), or those with other specific malignancies (e.g., carcinoma of the head or neck and lung), or individuals younger than age 17 years. QFT-Plus package inserts, up-to-date licensing information and product-specific disclaimers can be found at www.QuantiFERON.com.

Trademarks: QIAGEN®, Sample to Insight®, QuantiFERON®, QFT® (QIAGEN Group). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

PROM-13256-001 1115218 10/2018 © 2018, QIAGEN, all rights reserved.

Ordering www.qiagen.com/shop | Technical Support support.qiagen.com | Website www.QuantiFERON.com